Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ipilimumab Clear all
Recruiting Phase 1Phase 2 Interventional

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 12:53 AM EDT
Terminated Phase 2 Interventional Results available

MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

NCT01973608
View directory record Official record
Conditions
Melanoma
Interventions
MSB0010445 (0.3 milligram per kilogram [mg/kg]), MSB0010445 (1.0 mg/kg), MSB0010445 (1.8 mg/kg), MSB0010445 (2.4 mg/kg), Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 25, 2026, 12:53 AM EDT
Not listed Phase 1 Interventional

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT03068624
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 25, 2026, 12:53 AM EDT
Active, not recruiting Phase 2 Interventional

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

NCT06250335
View directory record Official record
Conditions
ICB-refractory Melanoma
Interventions
Prebiotic Food-Enriched Diet, Ipilimumab, Nivolumab
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 12:53 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

NCT03528408
View directory record Official record
Conditions
Melanoma, Ocular Melanoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Suthee Rapisuwon
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 25, 2026, 12:53 AM EDT
Terminated Phase 2 Interventional Results available

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

NCT02203604
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
aldesleukin, ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
CINJRegulatory
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
6
States / cities
Maywood, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 25, 2026, 12:53 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Decitabine, Ipilimumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
11
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 12:53 AM EDT
Completed No phase listed Observational

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

NCT04898751
View directory record Official record
Conditions
Cutaneous Toxicity From ICI Therapy
Interventions
Immune checkpoint inhibitor (ICI)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
2,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 25, 2026, 12:53 AM EDT
Terminated Phase 1 Interventional

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT03422094
View directory record Official record
Conditions
Glioblastoma
Interventions
NeoVax, Nivolumab, Ipilimumab, Research blood draw, Leukapheresis for research
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 12:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

NCT04091750
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab, Cabozantinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

NCT05041062
View directory record Official record
Conditions
Mesothelioma, Peritoneal Mesothelioma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 25, 2026, 12:53 AM EDT
Terminated Phase 1 Interventional

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03565406
View directory record Official record
Conditions
Melanoma
Interventions
Mocetinostat Induction Phase + Ipilimumab + Nivolumab, Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 25, 2026, 12:53 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762716
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 1 Interventional

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT02311920
View directory record Official record
Conditions
Gliosarcoma, Supratentorial Glioblastoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Temozolomide
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

NCT02737475
View directory record Official record
Conditions
Advanced Cancer
Interventions
BMS-986178, Nivolumab, Ipilimumab, Tetanus vaccine, DPV-001 vaccine, Cyclophosphamide
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

NCT01673854
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Vemurafenib
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 1 Interventional

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

NCT01445379
View directory record Official record
Conditions
Sarcoma, Wilm's Tumor, Lymphoma, Neuroblastoma
Interventions
Ipilimumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

NCT03029780
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Opdivo, Yervoy
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Jacksonville, Florida • Iowa City, Iowa • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 25, 2026, 12:53 AM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379
View directory record Official record
Conditions
Solid Tumor, Unresectable or Metastatic Melanoma
Interventions
CX-072, Ipilimumab
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

NCT01489059
View directory record Official record
Conditions
Melanoma
Interventions
BMS-982470 (recombinant interleukin-21), Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

NCT03158129
View directory record Official record
Conditions
Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

NCT00162123
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
19
States / cities
Tucson, Arizona • Laverne, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 25, 2026, 12:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

NCT03459222
View directory record Official record
Conditions
Advanced Cancer
Interventions
Relatlimab, Nivolumab, BMS-986205, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 25, 2026, 12:53 AM EDT